drugset / Trial / NCT02635360

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

NCT02635360 ↗

Phase 2 Completed 94 enrolled Linda R Duska Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.

Timeline

Start
2017-02-09
Primary completion
2021-01-01
Completion
2022-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Cisplatin Other / unclassified 40 mg —

Indications